SAR442168

Unassigned

New Medicines

Relapsing, recurrent multiple sclerosis (MS)

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective small molecule Bruton tyrosine kinase (BTK) inhibitor that can penetrate brain tissue
The prevalence of MS in the UK increased by about 2.4% per year from 1990 to 2010 reaching 285.8 per 100 000 in women and 113.1 per 100 000 in men by 2010 [2].
Relapsing, recurrent multiple sclerosis (MS)
Oral